What Is Vagus Nerve Stimulation?
Vagus nerve stimulation (VNS) is a neuromodulation technique that uses gentle electrical pulses to influence the activity of the vagus nerve and its extensive connections throughout the brain and body. Nearly 80–90% of vagal fibers carry sensory information toward the brain. Stimulation can modulate key regions involved in autonomic regulation and emotional processing. It also affects neuroimmune signaling. This makes the vagus nerve a highly effective gateway for therapeutic intervention.
This makes the vagus nerve a highly effective gateway for therapeutic intervention.
VNS is delivered through either implantable or non-invasive systems. Implantable cervical VNS involves placing a small pulse generator under the skin of the chest, which is connected to a helical electrode wrapped around the left vagus nerve in the neck. This allows tailored and long-term stimulation programs (Beekwilder & Beems, 2010).
Regardless of delivery mode, stimulation of vagal afferents activates brainstem hubs such as the nucleus tractus solitarius and locus coeruleus. These centers are crucial in regulating neurotransmitters like norepinephrine and serotonin. These pathways contribute to improved autonomic balance and enhanced cortical plasticity. Additionally, they modulate inflammatory signaling through mechanisms such as the cholinergic anti-inflammatory pathway.
Originally developed for drug-resistant epilepsy, VNS has evolved into a broad therapeutic platform. This evolution is supported by growing clinical and mechanistic evidence across neurological, psychiatric, autonomic, inflammatory, and pain-related disorders (Austelle et al., 2024; Goggins et al., 2022).
History of Vagus Nerve Stimulation
The development of vagus nerve stimulation (VNS) spans more than a century. It began with early attempts to electrically modulate the cervical vagus nerve to suppress seizures in the late 1800s. James Corning’s pioneering experiments utilized mechanical compression and rudimentary electrical stimulation of the carotid sheath. These efforts foreshadowed the concept of neuromodulation despite limited scientific understanding at that time (Austelle et al., 2024).
Modern clinical VNS emerged in the 1980s. Zabara and colleagues developed implantable stimulators and showed seizure-interrupting effects in canine epilepsy models. This marked the transition from theoretical interest to translational neuromodulation (Chen & Liu, 2025). The first human implantation occurred in 1988, followed by randomized controlled trials in the 1990s. These demonstrated clinically meaningful seizure reductions in drug-resistant epilepsy (Beekwilder & Beems, 2010).
The early 2000s and 2010s saw rapid diversification of VNS applications. Studies revealed neuromodulatory, anti-inflammatory, and neuroplasticity-enhancing effects. This catalyzed exploration of VNS for systemic inflammatory diseases and pain syndromes. It also included post-stroke rehabilitation (Fang et al., 2023).
Today, VNS stands as a foundational neuromodulation technology with a rich history marked by iterative scientific discovery, clinical translation, and expanding therapeutic scope—reflecting the evolving understanding of the vagus nerve as a central regulator of neural, autonomic, and immune networks.
Mechanisms of Action and Rationale for Neuromodulation
Vagus nerve stimulation (VNS) exerts its therapeutic effects by activating a highly interconnected neural–autonomic–immune network. Approximately 80–90% of vagal fibers are afferent, carrying sensory input from peripheral organs to the brain. Stimulation of these fibers initiates a cascade of activity beginning in the nucleus tractus solitarius (NTS). This projection extends to key regulatory centers including the locus coeruleus, raphe nuclei, hypothalamus, amygdala, and cortical regions. This broad anatomical reach provides the biological rationale for VNS as a tool capable of reshaping neural excitability, emotional regulation, autonomic tone, and immune function.
A central mechanism involves modulation of monoaminergic neurotransmission, particularly norepinephrine and serotonin. Activation of the locus coeruleus increases cortical norepinephrine release, enhancing arousal, attention, and synaptic plasticity—features directly relevant to epilepsy control, mood regulation, and functional recovery after neurological injury (Goggins et al., 2022; Chen & Liu, 2025). Parallel activation of raphe nuclei elevates serotonergic transmission, further supporting mood stabilization and neuroplastic changes.
VNS also influences cortical and subcortical excitability by generating network-level desynchronization, reducing hypersynchronous oscillations implicated in seizure propagation (Abdennadher et al., 2024). At the cellular level, VNS enhances activity-dependent plasticity through pathways that increase expression of plasticity-related genes, such as Arc, and through neuromodulator-driven strengthening of adaptive synaptic connections (Malley et al., 2024).
Another major component is the cholinergic anti-inflammatory pathway. This pathway is mediated by activation of vagal efferents that regulate cytokine production and immune-cell signaling. Through α7-nicotinic acetylcholine receptor–dependent mechanisms, VNS reduces levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This influences disease processes in chronic pain, autoimmune disorders, and systemic inflammatory states.
Together, these neurophysiological and immunomodulatory mechanisms support the rationale for VNS as a strategic method of influencing distributed neural circuits. By engaging multiple systems simultaneously, VNS achieves therapeutic effects not through a single pathway but through coordinated modulation of brain, autonomic, and immune networks.
Together, these neurophysiological and immunomodulatory mechanisms support the rationale for VNS as a strategic method of influencing distributed neural circuits. By engaging multiple systems simultaneously, VNS achieves therapeutic effects not through a single pathway but through coordinated modulation of brain, autonomic, and immune networks.
Indications
Vagus nerve stimulation (VNS) is used across a growing range of neurological, psychiatric, autonomic, inflammatory, and pain-related disorders, supported by both clinical trials and real-world evidence. The earliest and most established indication is drug-resistant epilepsy, where invasive cervical VNS significantly reduces seizure frequency and improves seizure severity in patients who are not candidates for resective surgery (Beekwilder & Beems, 2010; Goggins et al., 2022). Long-term follow-up demonstrates sustained improvement over years of therapy, making VNS an essential tool in the management of refractory epilepsy.
VNS is also approved for treatment-resistant depression, where neuromodulation of the locus coeruleus and serotonergic pathways contributes to clinically meaningful mood improvement. Its antidepressant effects have been supported by observational cohorts and mechanistic data showing enhanced monoaminergic neurotransmission (Austelle et al., 2024; Chen & Liu, 2025).
Non-invasive VNS techniques, including auricular (aVNS) and cervical (tcVNS) approaches, have expanded indications further. The FDA has cleared non-invasive VNS for migraine and cluster headache, where modulation of trigeminovascular and autonomic pathways leads to acute pain relief and reduced attack frequency (Goggins et al., 2022; Hilz, 2022).
Growing evidence also supports VNS for post-stroke motor rehabilitation, where pairing VNS with physical therapy enhances motor recovery via plasticity-related mechanisms, including neuromodulator-dependent strengthening of sensorimotor circuits (Malley et al., 2024; Austelle et al., 2024).
Beyond neurological disorders, VNS is increasingly considered for chronic pain conditions such as back pain, abdominal pain, and migraine, with meta-analyses demonstrating reductions in pain intensity and analgesic use, particularly with percutaneous auricular stimulation (Duff et al., 2024).
Emerging indications include systemic inflammatory diseases, autonomic dysfunction, heart failure, gastrointestinal motility disorders, and immune-mediated conditions, reflecting the growing recognition of the cholinergic anti-inflammatory pathway and the vagus nerve’s role in neuroimmune regulation (Fang et al., 2023).
Together, these indications highlight VNS as a multimodal therapy whose effectiveness is rooted in its capacity to target distributed neural and autonomic networks allowing a single modality to address a wide spectrum of dysregulated physiological systems.
Patient Selection, Preoperative Evaluation, and Brief Overview of Surgical Techniques
Appropriate patient selection is essential for optimizing outcomes with vagus nerve stimulation (VNS). This therapy is most effective when targeted to individuals whose clinical profiles match evidence-based indications. For drug-resistant epilepsy, candidates typically include patients who have failed at least two appropriately chosen antiseizure medications. They should also not be eligible for curative resective surgery due to multifocal, generalized, or eloquent-cortex seizure origins (Abdennadher et al., 2024; Beekwilder & Beems, 2010).
Preoperative evaluation includes comprehensive neurological and psychiatric assessment, medication history, seizure or symptom characterization, and evaluation for comorbidities that may influence outcomes. Imaging studies such as MRI help rule out structural pathology that may alter surgical candidacy, while cardiopulmonary assessment confirms fitness for anesthesia. Patients are also counseled regarding therapeutic expectations, device maintenance, and potential adverse effects to ensure informed decision-making (Goggins et al., 2022).
The surgical technique for invasive cervical VNS is well established and minimally invasive. Under general anesthesia, a small transverse incision is made along the left neck to expose the cervical vagus nerve, avoiding the right side to reduce the risk of bradyarrhythmia due to sinoatrial node innervation (Beekwilder & Beems, 2010). A helical electrode is wrapped around the nerve and connected via a subcutaneous tunneled lead to a pulse generator implanted in a subclavicular pocket. Stimulation parameters are programmed postoperatively and titrated gradually to therapeutic levels.
Because non-invasive VNS requires no surgery, its “preoperative” preparation centers on device education, appropriate placement training, and parameter optimization to ensure consistent and effective home-based application (Hilz, 2022).
Together, careful patient selection, structured evaluation, and standardized procedural steps form the foundation for safe and effective VNS therapy across indications. This approach optimizes outcomes and minimizes risks associated with the procedure.
Implementation Techniques and Targeting; Hardware & Technology Landscape; Programming Strategies and Clinical Optimization
Implementation of vagus nerve stimulation (VNS) relies on precise anatomical targeting, reliable hardware systems, and individualized programming strategies that optimize neuromodulatory effects while minimizing side effects. The standard surgical approach for invasive cervical VNS begins with exposure of the left cervical vagus nerve, chosen to reduce potential cardiac complications associated with right-sided sinoatrial node innervation (Beekwilder & Beems, 2010). Through a small transverse neck incision, the nerve is isolated within the carotid sheath, and a helical electrode consisting of cathode, anode, and anchoring spirals is wrapped circumferentially around the nerve. The electrode lead is tunneled subcutaneously and connected to a programmable pulse generator implanted in the upper chest. This minimally invasive procedure is typically completed under general anesthesia, with low complication rates and rapid recovery (Goggins et al., 2022).
Non-invasive modalities including auricular and cervical transcutaneous VNS utilize surface or clip-on electrodes placed over vagal branches. These devices avoid surgical implantation and rely on externally applied electrical pulses to activate vagal afferents.
The technology landscape has evolved significantly, with newer generators offering closed-loop sensing, automated duty cycling, and magnet-triggered stimulation for seizure interruption. Modern devices also incorporate battery-efficient designs, improved electrode biocompatibility, and adjustable stimulation waveforms, enhancing both durability and patient comfort (Austelle et al., 2024).
Programming strategies focus on balancing therapeutic efficacy with tolerability. Typical initial parameters include low-output stimulation with gradual titration over weeks to reach individualized thresholds. Adjustments are guided by clinical response, side-effect profiles, and device diagnostics. For invasive VNS, parameters such as pulse width, frequency, duty cycle, and output amplitude directly influence neural recruitment patterns (Abdennadher et al., 2024). In contrast, non-invasive systems rely on optimized electrode placement, stimulation intensity calibration, and structured usage protocols to ensure consistent activation of vagal fibers (Hilz, 2022).
Clinical optimization is iterative and often interdisciplinary. Long-term follow-up allows refinement of stimulation settings, integration with rehabilitative therapies, and monitoring for device-related complications collectively enabling VNS to achieve durable neuromodulatory benefits across diverse indications.
Clinical Outcomes (Cross-Indication Summary)
Vagus nerve stimulation (VNS) has demonstrated clinically meaningful benefits across neurological, psychiatric, autonomic, inflammatory, and pain-related conditions. Outcomes are supported by randomized trials, long-term cohort studies, and expanding global utilization. In drug-resistant epilepsy, invasive cervical VNS consistently yields a 40–60% median long-term seizure reduction. Responder rates increase over time due to cumulative neuromodulatory effects (Beekwilder & Beems, 2010). Real-world registries confirm durable improvement in seizure frequency, severity, and quality of life, particularly in patients with multifocal or generalized epilepsy syndromes (Austelle et al., 2024).
In treatment-resistant depression, VNS provides progressive, sustained antidepressant effects over months to years. Observational cohorts show response rates exceeding those achieved with conventional pharmacotherapy alone. These improvements correlate with the modulatory impact of VNS on monoaminergic systems and autonomic balance (Goggins et al., 2022).
For headache disorders, non-invasive VNS—especially transcutaneous cervical stimulation—improves both acute pain relief and attack frequency in migraine and cluster headache. Clinical trials demonstrate reductions in attack severity and rescue medication use. This supports its role as an FDA-cleared modality (Hilz, 2022).
In post-stroke motor rehabilitation, pairing VNS with task-specific therapy significantly enhances upper-limb motor recovery. Controlled human studies and mechanistic animal models show amplified neuroplasticity, including strengthened corticospinal connectivity and increased expression of plasticity-related genes such as Arc (Malley et al., 2024).
VNS has also shown benefit in chronic pain. Meta-analyses reveal reductions in pain intensity and analgesic dependence. Notably, percutaneous auricular VNS produces particularly strong effect sizes (Duff et al., 2024). Its anti-inflammatory properties further position VNS as a potential therapy for systemic inflammatory and autonomic dysfunction disorders (Fang et al., 2023).
Real-world evidence highlights the safety, tolerability, and adaptability of VNS across healthcare settings. Device longevity, iterative programming, and integration with multimodal therapy contribute to high patient retention and sustained outcomes. Non-invasive VNS has expanded accessibility worldwide, enabling use in outpatient clinics, rehabilitation centers, and home-based management.
Global utilization has grown steadily, with tens of thousands of implanted devices used annually across North America, Europe, and Asia, and rapid adoption of non-invasive VNS in regions prioritizing cost-effective neuromodulation. Market expansion parallels broader recognition of the vagus nerve as a therapeutic entry point for disorders involving dysregulated neural excitability, impaired plasticity, or chronic inflammation establishing VNS as a cornerstone technology in the evolving global neuromodulation landscape.
Side Effects, Complications, and Risk Mitigation and Ethical, Psychological, and Societal Considerations
Vagus nerve stimulation (VNS) is generally well tolerated, with most adverse effects being mild, predictable, and stimulation-related. Common side effects include hoarseness, throat discomfort, cough, paresthesia, and transient dyspnea during active stimulation, reflecting activation of nearby laryngeal and respiratory pathways (Beekwilder & Beems, 2010; Goggins et al., 2022). These effects typically diminish over time or with parameter adjustment. Surgical complications though uncommon may include infection, hematoma, lead fracture, or generator pocket discomfort. Careful surgical technique, postoperative wound monitoring, and gradual titration reduce these risks (Austelle et al., 2024).
For non-invasive VNS, side effects are minimal and primarily limited to local skin irritation or tingling sensations at the stimulation site (Hilz, 2022; Duff et al., 2024). Proper electrode placement training and intensity calibration help minimize discomfort.
Ethical considerations center on ensuring informed consent, particularly for patients with refractory neurological or psychiatric conditions who may have limited treatment alternatives. Clinicians must balance therapeutic optimism with realistic expectations and transparent discussion of uncertainties (Fang et al., 2023). Psychological aspects include adjusting to an implanted device, managing chronic illness, and potential stigma associated with visible hardware or neuromodulation therapy.
From a societal standpoint, equitable access to VNS remains a challenge due to cost variability across regions and healthcare systems. The growing availability of non-invasive technologies may improve accessibility and reduce disparities. Collectively, thoughtful risk mitigation and ethical practice are essential for maximizing the safe, effective, and socially responsible use of VNS.
Future Directions and Emerging Paradigms
Future developments in vagus nerve stimulation (VNS) are driven by advances in device engineering and neurophysiology. This evolving understanding emphasizes the vagus nerve’s role in multimodal regulation across the brain–body axis. One major trajectory is the refinement of closed-loop VNS systems. These systems deliver stimulation in response to physiological markers such as heart rate variability and respiratory patterns. Early prototypes already demonstrate enhanced therapeutic specificity and reduced side-effect profiles compared to traditional open-loop systems (Austelle et al., 2024).
Another emerging paradigm involves target-specific neuromodulation, supported by research showing differential activation of vagal afferent subtypes and distinct projection pathways. Novel electrode designs, current steering, and selective waveform modulation aim to preferentially recruit therapeutic fibers while minimizing off-target activation (Chen & Liu, 2025). Similarly, optimized stimulation dosing guided by mechanistic insights into noradrenergic, serotonergic, and anti-inflammatory signaling may enable personalized treatment algorithms based on biomarker responses (Fang et al., 2023).
The rapid growth of non-invasive VNS continues to open new avenues for scalable, home-based, and preventive neuromodulation. Ongoing clinical trials in chronic pain, cardiovascular regulation, immune disorders, and cognitive aging suggest the potential for VNS to become a universal tool for autonomic and neuroimmune modulation (Hilz, 2022; Duff et al., 2024). Integration with digital health platforms including wearable monitoring, mobile-app coaching, and remote titration may transform VNS into a hybrid therapeutic model combining device-based neuromodulation with real-time data analytics.
A broader research frontier explores cross-system therapeutic applications, including modulation of gut–brain signaling, metabolic regulation, inflammatory cascades, and stress-related disorders. Preclinical findings of enhanced cortical plasticity and immune modulation reflect the possibility of VNS as a platform technology for regenerative neuroscience and multisystem rehabilitation (Malley et al., 2024).
As these innovations mature, ethical considerations such as data privacy, equitable access, and responsible use outside traditional medical settings will shape implementation. Altogether, the future of VNS lies in increasingly precise, personalized, and integrative neuromodulation strategies capable of addressing complex brain–body disorders at scale.
Summary
Vagus nerve stimulation (VNS) has evolved into a versatile neuromodulation platform capable of influencing neural, autonomic, and immune pathways through targeted activation of predominantly afferent vagal fibers. Its physiological foundation rooted in projections from the vagus nerve to brainstem hubs such as the nucleus tractus solitarius, locus coeruleus, and raphe nuclei provides a mechanistic rationale for its broad therapeutic potential across neurological, psychiatric, inflammatory, and pain-related disorders (Fang et al., 2023; Abdennadher et al., 2024). The development of both implantable and non-invasive systems has significantly expanded access, enabling tailored stimulation approaches that vary from surgically implanted cervical leads to transcutaneous auricular devices (Hilz, 2022; Beekwilder & Beems, 2010).
Clinical evidence demonstrates robust and sustained benefits in drug-resistant epilepsy, the earliest and most extensively studied indication. Here, VNS reduces seizure burden and improves long-term outcomes (Austelle et al., 2024). In treatment-resistant depression, VNS enhances neurotransmitter balance and autonomic regulation. This supports meaningful functional recovery over time (Goggins et al., 2022).
While VNS is generally safe, careful patient selection, structured preoperative evaluation, and individualized programming remain central to optimizing outcomes. Ethical considerations include ensuring informed consent, managing expectations, and addressing disparities in access to treatment.
While VNS is generally safe, careful patient selection, structured preoperative evaluation, and individualized programming remain central to optimizing outcomes and reducing risks. Ethical considerations including ensuring informed consent, managing expectations, and addressing disparities in Access will become increasingly important as VNS technologies proliferate and move beyond specialized centers.
Looking forward, the emergence of closed-loop systems, biomarker-guided dosing, selective fiber targeting, and digital health integrated neuromodulation signals a new era for Vagus Nerve Stimulation. In this era, VNS may become a cornerstone therapy across brain–body disorders.
As global utilization continues to rise, VNS stands at the intersection of neuroscience, immunology, and bioengineering. This represents not only a proven treatment modality but also a transformative platform shaping the future of personalized neuromodulation.
References
This comprehensive overview of Vagus Nerve Stimulation highlights its importance in addressing various neurological and psychiatric conditions.
Abdennadher, S., Fang, J., Zhang, Y., Li, X., & Rong, P. (2024). Transcutaneous vagus nerve stimulation: Mechanisms and clinical applications. Brain Sciences, 14(675), 1–20.
Austelle, C. W., Cox, S. S., Wills, K. E., & Badran, B. W. (2024). Vagus nerve stimulation (VNS): Recent advances and future directions. Clinical Autonomic Research, 34, 529–547.
Beekwilder, J., & Beems, T. (2010). Overview of the clinical applications of vagus nerve stimulation. Journal of Clinical Neurophysiology, 27(2), 130–138.
Chen, Z., & Liu, K. (2025). Mechanism and applications of vagus nerve stimulation. Current Issues in Molecular Biology, 47(122), 1–21.
Duff, C. J., et al. (2024). Efficacy of auricular neuromodulation for pain management: A systematic review and meta-analysis. Scientific Reports, 14, Article 70091.
Fang, J., Chen, Q., et al. (2023). Neuroimmune pathways associated with vagus nerve stimulation: Implications for inflammatory and neurological disease. Frontiers in Aging Neuroscience, 15, 1173987.
Goggins, E., Mitani, S., & Tanaka, S. (2022). Clinical perspectives on vagus nerve stimulation: Present and future. Clinical Science, 136, 695–709.
Hilz, M. J. (2022). Vagus nerve stimulation: Physiological mechanisms and clinical implications. Clinical Autonomic Research, 32, 1–15.
Malley, J. C., et al. (2024). Vagus nerve stimulation promotes cortical plasticity and functional recovery: Translational insights for neurorehabilitation. Current Issues in Molecular Biology, 47, Article 6578.
Rong, P., Fang, J., & Zhang, Y. (2024). Auricular vagus nerve stimulation: Neural mechanisms and clinical potential. Cellular & Molecular Biology, 47, 122–140.